Interleukin‑32 regulates downstream molecules and promotes the invasion of pancreatic cancer cells

Takagi,Kohji; Shimomura,Akiko; Imura,Johji; Mori,Hisashi; Noguchi,Akira; Tanaka,Shinichi; Minamisaka,Takashi; Nishida,Takeshi; Hatta,Hideki; Nakajima,Takahiko

doi:10.3892/ol.2021.13132

Interleukin‑32 regulates downstream molecules and promotes the invasion of pancreatic cancer cells

Authors:
- Kohji Takagi
- Akiko Shimomura
- Johji Imura
- Hisashi Mori
- Akira Noguchi
- Shinichi Tanaka
- Takashi Minamisaka
- Takeshi Nishida
- Hideki Hatta
- Takahiko Nakajima
View Affiliations

Affiliations: Department of Diagnostic Pathology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama 930‑0194, Japan, Department of Molecular Neuroscience, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama 930‑0194, Japan
Published online on: November 11, 2021 https://doi.org/10.3892/ol.2021.13132
Article Number: 14
Copyright: © Takagi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic cancer is a malignant neoplasm with high invasiveness and poor prognosis. In a previous study, a highly invasive pancreatic cancer cell line was established and found to feature enhanced interleukin‑32 (IL‑32) expression. However, whether IL‑32 promotes the invasiveness by enhancing or suppressing the expression of IL‑32 through regulating downstream molecules was unclear. To investigate the effect of IL‑32, cells were established with high levels of expression or downregulated IL‑32; their invasive ability was measured using a real‑time measurement system and the expression of some candidate downstream molecules involved in invasion was evaluated in the two cell types. The morphological changes in both cell types and the localization of IL‑32 expression in pancreatic cancer tissues were studied using immunohistochemistry. Among the several splice variants of IL‑32, cells transfected with the ε isoform had increased invasiveness, whereas the IL‑32‑suppressed cells had reduced invasiveness. Several downstream molecules, whose expression was changed in the two cell types, were monitored. Notably, changes of E‑cadherin, CLDN1, CD44, CTGF and Wnt were documented. The morphologies of the two cell types differed from the original cell line. Immunohistochemically, the expression of IL‑32 was observed only in tumor cells and not in normal pancreatic cells. In conclusion, IL‑32 was found to promote the invasiveness of pancreatic cancer cells by regulating downstream molecules.

View Figures

View References

1	Vincent A, Herman J, Schulick R, Hruban RH and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011. View Article : Google Scholar : PubMed/NCBI
2	Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH, et al: Pancreatic cancer. Nat Rev Dis Primers. 2:160222016. View Article : Google Scholar : PubMed/NCBI
3	Pelosi E, Castelli G and Testa U: Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. Biomedicines. 5:652017. View Article : Google Scholar : PubMed/NCBI
4	Hruban RH, Pitman MB and Kimstra DS: Tumors of the Pancreas, Afip Atlas of Tumor Pathology. (6th edition). American Registry of Pathology. (Washington, DC). 1201–126. 2007.
5	Luo J, Chen XQ and Li P: The Role of TGF-β and Its Receptors in Gastrointestinal Cancers. Transl Oncol. 12:475–484. 2019. View Article : Google Scholar : PubMed/NCBI
6	Miyazono K, Katsuno Y, Koinuma D, Ehata S and Morikawa M: Intracellular and extracellular TGF-β signaling in cancer: Some recent topics. Front Med. 12:387–411. 2018. View Article : Google Scholar : PubMed/NCBI
7	Takagi K, Imura J, Shimomura A, Noguchi A, Minamisaka T, Tanaka S, Nishida T, Hatta H and Nakajima T: Establishment of highly invasive pancreatic cancer cell lines and the expression of IL-32. Oncol Lett. 20:2888–2896. 2020. View Article : Google Scholar : PubMed/NCBI
8	Nisticò P, Bissell MJ and Radisky DC: Epithelial-mesenchymal transition: General principles and pathological relevance with special emphasis on the role of matrix metalloproteinases. Cold Spring Harb Perspect Biol. 4:42012. View Article : Google Scholar : PubMed/NCBI
9	Fuxe J, Vincent T and Garcia de Herreros A: Transcriptional crosstalk between TGF-β and stem cell pathways in tumor cell invasion: Role of EMT promoting Smad complexes. Cell Cycle. 9:2363–2374. 2010. View Article : Google Scholar : PubMed/NCBI
10	Chen J, Wang S, Su J, Chu G, You H, Chen Z, Sun H, Chen B and Zhou M: Interleukin-32α inactivates JAK2/STAT3 signaling and reverses interleukin-6-induced epithelial-mesenchymal transition, invasion, and metastasis in pancreatic cancer cells. OncoTargets Ther. 9:4225–4237. 2016. View Article : Google Scholar : PubMed/NCBI
11	Nishida A, Andoh A, Inatomi O and Fujiyama Y: Interleukin-32 expression in the pancreas. J Biol Chem. 284:17868–17876. 2009. View Article : Google Scholar : PubMed/NCBI
12	Kyuno D, Takasawa A, Kikuchi S, Takemasa I, Osanai M and Kojima T: Role of tight junctions in the epithelial-to-mesenchymal transition of cancer cells. Biochim Biophys Acta Biomembr. 1863:1835032021. View Article : Google Scholar : PubMed/NCBI
13	Chen C, Zhao S, Karnad A and Freeman JW: The biology and role of CD44 in cancer progression: Therapeutic implications. J Hematol Oncol. 11:642018. View Article : Google Scholar : PubMed/NCBI
14	Jacobson A and Cunningham JL: Connective tissue growth factor in tumor pathogenesis. Fibrogenesis Tissue Repair. 5 (Suppl 1):S82012. View Article : Google Scholar : PubMed/NCBI
15	Scheau C, Badarau IA, Costache R, Caruntu C, Mihai GL, Didilescu AC, Constantin C and Neagu M: The Role of Matrix Metalloproteinases in the Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma. Anal Cell Pathol (Amst). 2019:94239072019.PubMed/NCBI
16	Pukrop T, Klemm F, Hagemann T, Gradl D, Schulz M, Siemes S, Trümper L and Binder C: Wnt 5a signaling is critical for macrophage-induced invasion of breast cancer cell lines. Proc Natl Acad Sci USA. 103:5454–5459. 2006. View Article : Google Scholar : PubMed/NCBI
17	Takeshita A, Iwai S, Morita Y, Niki-Yonekawa A, Hamada M and Yura Y: Wnt5b promotes the cell motility essential for metastasis of oral squamous cell carcinoma through active Cdc42 and RhoA. Int J Oncol. 44:59–68. 2014. View Article : Google Scholar : PubMed/NCBI
18	Agnihotri N, Kumar S and Mehta K: Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer. Breast Cancer Res. 15:2022013. View Article : Google Scholar : PubMed/NCBI
19	Ito T, Hayashida M, Kobayashi S, Muto N, Hayashi A, Yoshimura T and Mori H: Serine racemase is involved in d-aspartate biosynthesis. J Biochem. 160:345–353. 2016. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Lee J, Kim KE, Cheon S, Song JH, Houh Y, Kim TS, Gil M, Lee KJ, Kim S, Kim D, et al: Interleukin-32α induces migration of human melanoma cells through downregulation of E-cadherin. Oncotarget. 7:65825–65836. 2016. View Article : Google Scholar : PubMed/NCBI
22	Sloot YJE, Rabold K, Ulas T, De Graaf DM, Heinhuis B, Händler K, Schultze JL, Netea MG, Smit JWA, Joosten LAB, et al: Interplay between thyroid cancer cells and macrophages: Effects on IL-32 mediated cell death and thyroid cancer cell migration. Cell Oncol (Dordr). 42:691–703. 2019. View Article : Google Scholar : PubMed/NCBI
23	Sloot YJE, Smit JW, Joosten LAB and Netea-Maier RT: Insights into the role of IL-32 in cancer. Semin Immunol. 38:24–32. 2018. View Article : Google Scholar : PubMed/NCBI
24	Tsai CY, Wang CS, Tsai MM, Chi HC, Cheng WL, Tseng YH, Chen CY, Lin CD, Wu JI, Wang LH, et al: Interleukin-32 increases human gastric cancer cell invasion associated with tumor progression and metastasis. Clin Cancer Res. 20:2276–2288. 2014. View Article : Google Scholar : PubMed/NCBI
25	Yousif NG, Al-Amran FG, Hadi N, Lee J and Adrienne J: Expression of IL-32 modulates NF-κB and p38 MAP kinase pathways in human esophageal cancer. Cytokine. 61:223–227. 2013. View Article : Google Scholar : PubMed/NCBI
26	Zhou Y, Hu Z, Li N and Jiang R: Interleukin-32 stimulates osteosarcoma cell invasion and motility via AKT pathway-mediated MMP-13 expression. Int J Mol Med. 35:1729–1733. 2015. View Article : Google Scholar : PubMed/NCBI
27	Weinberg RA: The Biology of Cancer. (2nd edition). Garland Science. (Cambridge, MA). 658–691. 2013.
28	Ikenouchi J, Matsuda M, Furuse M and Tsukita S: Regulation of tight junctions during the epithelium-mesenchyme transition: Direct repression of the gene expression of claudins/occludin by Snail. J Cell Sci. 116:1959–1967. 2003. View Article : Google Scholar : PubMed/NCBI
29	Zeng Q, Li S, Zhou Y, Ou W, Cai X, Zhang L, Huang W, Huang L and Wang Q: Interleukin-32 contributes to invasion and metastasis of primary lung adenocarcinoma via NF-kappaB induced matrix metalloproteinases 2 and 9 expression. Cytokine. 65:24–32. 2014. View Article : Google Scholar : PubMed/NCBI
30	Zhao WB, Wang QL, Xu YT, Xu SF, Qiu Y and Zhu F: Overexpression of interleukin-32α promotes invasion by modulating VEGF in hepatocellular carcinoma. Oncol Rep. 39:1155–1162. 2018.PubMed/NCBI
31	Klingbeil P, Marhaba R, Jung T, Kirmse R, Ludwig T and Zöller M: CD44 variant isoforms promote metastasis formation by a tumor cell-matrix cross-talk that supports adhesion and apoptosis resistance. Mol Cancer Res. 7:168–179. 2009. View Article : Google Scholar : PubMed/NCBI
32	Tsai HC, Su HL, Huang CY, Fong YC, Hsu CJ and Tang CH: Correction: CTGF increases matrix metalloproteinases expression and subsequently promotes tumor metastasis in human osteosarcoma through down-regulating miR-519d. Oncotarget. 11:4922020. View Article : Google Scholar : PubMed/NCBI
33	Wang X, Yu Z, Zhou Q, Wu X, Chen X, Li J, Zhu Z, Liu B and Su L: Tissue transglutaminase-2 promotes gastric cancer progression via the ERK1/2 pathway. Oncotarget. 7:7066–7079. 2016. View Article : Google Scholar : PubMed/NCBI